Last reviewed · How we verify
sublingual immunotherapy
Sublingual immunotherapy delivers allergen extracts under the tongue to induce immune tolerance and reduce allergic responses.
Sublingual immunotherapy delivers allergen extracts under the tongue to induce immune tolerance and reduce allergic responses. Used for Allergic rhinitis, Allergic asthma.
At a glance
| Generic name | sublingual immunotherapy |
|---|---|
| Also known as | SLITone(TM) Birch |
| Sponsor | University of Genova |
| Drug class | Allergen immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
This treatment works by gradually exposing the immune system to small, increasing doses of allergen antigens placed under the tongue, where specialized immune cells promote tolerance rather than allergic sensitization. Over time, this desensitization reduces the production of allergic antibodies (IgE) and increases regulatory T cells and blocking antibodies (IgG4), leading to decreased allergic symptoms upon natural allergen exposure.
Approved indications
- Allergic rhinitis
- Allergic asthma
Common side effects
- Oral pruritus
- Throat irritation
- Mild local swelling
- Gastrointestinal symptoms
Key clinical trials
- Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project (NA)
- Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy (PHASE1, PHASE2)
- Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites (PHASE2)
- Serum sST2/ miR-223 as a Dual Biomarker for Disease Activity & Clinical Efficacy of SLIT in HDM-Induced Allergic Rhinitis (PHASE1)
- Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df (PHASE3)
- Sublingual Milk Immunotherapy in Children (NA)
- Identification of B Regulatory Cells by Flow Cytometry
- UNC Cashew Sublingual Immunotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sublingual immunotherapy CI brief — competitive landscape report
- sublingual immunotherapy updates RSS · CI watch RSS
- University of Genova portfolio CI